NZ516261A - Mag expression promoters - Google Patents
Mag expression promotersInfo
- Publication number
- NZ516261A NZ516261A NZ516261A NZ51626100A NZ516261A NZ 516261 A NZ516261 A NZ 516261A NZ 516261 A NZ516261 A NZ 516261A NZ 51626100 A NZ51626100 A NZ 51626100A NZ 516261 A NZ516261 A NZ 516261A
- Authority
- NZ
- New Zealand
- Prior art keywords
- expression promoters
- alkyl
- mag expression
- compounds
- mag
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Compounds Of Unknown Constitution (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP14433699 | 1999-05-25 | ||
PCT/JP2000/003373 WO2000071119A1 (fr) | 1999-05-25 | 2000-05-25 | Promoteurs de l'expression de la glycoproteine associee a la myeline (mag) |
Publications (1)
Publication Number | Publication Date |
---|---|
NZ516261A true NZ516261A (en) | 2003-11-28 |
Family
ID=15359751
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NZ516261A NZ516261A (en) | 1999-05-25 | 2000-05-25 | Mag expression promoters |
Country Status (21)
Country | Link |
---|---|
US (2) | US7166630B2 (de) |
EP (1) | EP1186296B1 (de) |
KR (1) | KR100660955B1 (de) |
CN (1) | CN1160072C (de) |
AT (1) | ATE359780T1 (de) |
AU (1) | AU774471B2 (de) |
BG (1) | BG106254A (de) |
BR (1) | BR0011551A (de) |
CA (1) | CA2373967A1 (de) |
CZ (1) | CZ20014203A3 (de) |
DE (1) | DE60034448D1 (de) |
EE (1) | EE200100621A (de) |
HK (1) | HK1044721A1 (de) |
HU (1) | HUP0201485A3 (de) |
IL (1) | IL146726A0 (de) |
IS (1) | IS6173A (de) |
MX (1) | MXPA01012188A (de) |
NO (1) | NO20015733L (de) |
NZ (1) | NZ516261A (de) |
RU (1) | RU2241454C2 (de) |
WO (1) | WO2000071119A1 (de) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1354664B1 (de) | 2002-04-20 | 2010-11-17 | Haas Laser GmbH & Co. KG | Einrichtung zur Überwachung eines optischen Elements eines Bearbeitungskopfes einer Maschine zur thermischen Bearbeitung eines Werkstücks |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19541146A1 (de) | 1995-10-25 | 1997-04-30 | Schering Ag | Imidazolderivate und deren Verwendung als Stickstoffmonoxid-Synthase-Inhibitoren |
BR9612316A (pt) * | 1995-12-27 | 1999-07-13 | Yoshitomi Pharmaceutical | Agente para profilaxia e tratamento de complicações diabéticas |
-
2000
- 2000-05-25 IL IL14672600A patent/IL146726A0/xx unknown
- 2000-05-25 RU RU2001134893/15A patent/RU2241454C2/ru not_active IP Right Cessation
- 2000-05-25 BR BR0011551-7A patent/BR0011551A/pt not_active IP Right Cessation
- 2000-05-25 EP EP00931568A patent/EP1186296B1/de not_active Expired - Lifetime
- 2000-05-25 CN CNB008092354A patent/CN1160072C/zh not_active Expired - Fee Related
- 2000-05-25 AT AT00931568T patent/ATE359780T1/de not_active IP Right Cessation
- 2000-05-25 KR KR1020017015051A patent/KR100660955B1/ko not_active IP Right Cessation
- 2000-05-25 CZ CZ20014203A patent/CZ20014203A3/cs unknown
- 2000-05-25 EE EEP200100621A patent/EE200100621A/xx unknown
- 2000-05-25 WO PCT/JP2000/003373 patent/WO2000071119A1/ja active IP Right Grant
- 2000-05-25 HU HU0201485A patent/HUP0201485A3/hu unknown
- 2000-05-25 CA CA002373967A patent/CA2373967A1/en not_active Abandoned
- 2000-05-25 MX MXPA01012188A patent/MXPA01012188A/es unknown
- 2000-05-25 NZ NZ516261A patent/NZ516261A/xx unknown
- 2000-05-25 AU AU49497/00A patent/AU774471B2/en not_active Ceased
- 2000-05-25 DE DE60034448T patent/DE60034448D1/de not_active Expired - Lifetime
-
2001
- 2001-11-23 IS IS6173A patent/IS6173A/is unknown
- 2001-11-23 NO NO20015733A patent/NO20015733L/no unknown
- 2001-12-20 BG BG106254A patent/BG106254A/xx unknown
-
2002
- 2002-08-29 HK HK02106416.1A patent/HK1044721A1/zh unknown
-
2004
- 2004-10-22 US US10/969,885 patent/US7166630B2/en not_active Expired - Fee Related
-
2006
- 2006-08-07 US US11/499,785 patent/US20060270712A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
NO20015733L (no) | 2002-01-11 |
MXPA01012188A (es) | 2003-06-30 |
RU2241454C2 (ru) | 2004-12-10 |
IL146726A0 (en) | 2002-07-25 |
AU4949700A (en) | 2000-12-12 |
WO2000071119A1 (fr) | 2000-11-30 |
CZ20014203A3 (cs) | 2002-06-12 |
HUP0201485A3 (en) | 2004-01-28 |
BR0011551A (pt) | 2002-04-02 |
HK1044721A1 (zh) | 2002-11-01 |
AU774471B2 (en) | 2004-07-01 |
EP1186296A4 (de) | 2004-12-22 |
US20050090531A1 (en) | 2005-04-28 |
EP1186296A1 (de) | 2002-03-13 |
NO20015733D0 (no) | 2001-11-23 |
ATE359780T1 (de) | 2007-05-15 |
US7166630B2 (en) | 2007-01-23 |
CN1356900A (zh) | 2002-07-03 |
KR20020015332A (ko) | 2002-02-27 |
CA2373967A1 (en) | 2000-11-30 |
US20060270712A1 (en) | 2006-11-30 |
EP1186296B1 (de) | 2007-04-18 |
EE200100621A (et) | 2003-02-17 |
DE60034448D1 (de) | 2007-05-31 |
IS6173A (is) | 2001-11-23 |
CN1160072C (zh) | 2004-08-04 |
KR100660955B1 (ko) | 2006-12-26 |
BG106254A (en) | 2002-08-30 |
HUP0201485A2 (en) | 2002-08-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2063289T3 (es) | (2-imidazolin-2-ilamino) tetrahidroquinoxalinas y metodos para usarlas. | |
DE60336850D1 (en) | Substituierte arylcyclopropylacetamide als glucokinaseaktivatoren | |
HRP20050432A2 (en) | Novel medicaments for the treatment of chronic obstructive pulmonary diseases | |
AP2088A (en) | Phenethanolamine derivatives for treatment of respiratory diseases | |
NZ505362A (en) | 4-hydroxyquinoline-3-carboxamides and -hydrazides useful as antiviral agents | |
MXPA03011981A (es) | 3-fluoruro-pirrolidinas como agentes antidiabeticos. | |
HUP0204405A2 (en) | Water soluble prodrugs of azole compounds | |
MXPA02007632A (es) | Derivados de 2-benzotiazolil urea y su uso como inhibidores de proteina cinasa. | |
HRP20040371B1 (en) | Thiopene- amd thiazolesulfonamides as antineoplastic agents | |
CA2282585A1 (en) | Pyrazine compounds | |
MXPA05011207A (es) | Uso de derivados de 2,4-dihidro-[1,2,4]triazol-3-tiona como inhibidores de la enzima mieloperoxidasa (mpo). | |
MY143353A (en) | Diazole derivatives | |
MXPA04010055A (es) | Derivados de tioxantina como inhibidores de mieloperoxidasa. | |
MXPA02004448A (es) | Derivados de imidazopiridina como inhibidores de la fosfodiesterasa vii. | |
SE8900039L (sv) | Isokinolinderivat, deras framstaellning och deras anvaendning | |
GEP20074045B (en) | (4-phenyl) piperidin-3-yl-phenylcarboxylate derivatives and related compounds as beta-secretase inhibitors for the treatment of alzheimer's disease | |
MXPA05005790A (es) | Aminoalcoxiindoles como ligandos del receptor 5-ht6 para el tratamiento de enfermedades del sistema nervioso central. | |
ES8506652A1 (es) | Un metodo de preparar dihidrobenzopirrolbenzodiazepinas | |
ES2180449A1 (es) | Derivados de aril (o heteroaril) azolilcarbinoles para el tratamiento de la incontinencia urinaria. | |
NZ516261A (en) | Mag expression promoters | |
CA2452036A1 (en) | 6-'2-(phosphonomethoxy) alkoxy pyrimidine derivatives having antiviral activity | |
ATE308540T1 (de) | Antithrombosemittel | |
DE60100314D1 (de) | 7-carboxylatische flavon derivate, verfahren zur herstellung und verwendung als heilmittel | |
AU546260B2 (en) | Diphenylbutyl-1-acylpiperazines | |
NZ533795A (en) | Carboxamidine derivatives and their use in the treatment of vascular diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PSEA | Patent sealed | ||
RENW | Renewal (renewal fees accepted) | ||
S38A | Application for proceedings under section 38 (amendment of specification with leave of commissioner) |
Free format text: BY WAY OF CORRECTION |
|
S38C | Proceedings under section 38 (amendment of specification with leave of commissioner): specification amended | ||
RENW | Renewal (renewal fees accepted) |